# A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants

> **NCT07668154** · PHASE2 · RECRUITING · sponsor: **Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- HNSCC

## Interventions

- **DRUG:** SKB571
- **DRUG:** Pembrolizumab
- **DRUG:** carboplatin
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT07668154
- **Lead sponsor:** Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-27
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668154, "A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07668154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*